Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California. Show more
1300 Rancho Conejo Boulevard, Thousand Oaks, CA, 91320, United States
Market Cap
1.40B
52 Wk Range
$17.22 - $25.93
Previous Close
$21.11
Open
$21.11
Volume
418,233
Day Range
$20.01 - $21.33
Enterprise Value
1.374B
Cash
55.0M
Avg Qtr Burn
-21.28M
Insider Ownership
4.98%
Institutional Own.
75.43%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
LTG-321 Details Osteoarthritis pain | Phase 2 Data readout | |
Onzotrigine (formerly LTG-001) Details Moderate-to-severe acute postoperative pain following bunionectomy | Phase 2 Initiation |
